パーキンソン病治療薬の市場規模、シェア＆動向分析レポート：薬物クラス別（カルビドパ・レボドパ、抗コリン剤）、流通チャネル別（病院薬局、小売薬局）、地域別、セグメント別予測、2022～2030年版

パーキンソン病治療薬市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界のパーキンソン病治療薬市場規模は2030年までに119億8000万米ドルに達し、2022年から2030年までCAGR12.1％で成長すると予測されています。これは、PDの新規治療法の研究開発への投資が増加していることに起因していると考えられます。2021年8月、パーキンソン財団は、PDの新規治療法や治療法の開発を目的とした29の研究プロジェクトに対し、研究助成金として4300万米ドルを投資することを発表しました。さらに、2021年5月、パーキンソン財団は、パーキンソン病（PD）に関する研究、ケア、教育プログラムのために1,000万米ドルを投資することを発表しました。この投資は、PDに悩む人々への啓発と遺伝子検査の無償提供を支援するものと考えられます。

このような投資イニシアティブは、業界の成長を後押しすると期待されています。過去10年間、PD治療分野では重要な研究開発活動が行われ、革新的なドラッグデリバリー方法の開発につながりました。副作用が少ないため、これらの最先端のドラッグデリバリーシステムは既存のものを凌駕しています。さらに、患者のコンプライアンス向上により、これらの手法の処方率が上昇しており、業界の拡大に拍車をかけています。さらに、主要な製薬会社は、国際市場における疾患治療の需要増に対応するため、製品の開発、製造＆商業化のためのコラボレーションやパートナーシップなどの取り組みを行っています。

例えば、2021年11月、STADA ArzneimittelとBioglanは、PD患者の治療に使用される医薬品Lecigon（レボドパ/カルビドパ/エンタカポン）の生産能力を拡大するためにパートナーシップを結びました。このように、PD患者の治療に使用される医薬品に対する需要の増加が、業界の成長を促進すると予想されます。しかし、神経科医の数が限られているため、患者の待ち時間が長くなったり、病院での神経外科医の新規採用が困難であったりといった問題が生じています。また、現在開業している神経科医の中には、メディケイドの新規患者の受け入れを避ける医師もいるため、他の医師への変更を希望する患者にとっては困難な状況となっています。米国神経学会（AAN）のレポートによると、2025年までに神経科医が約19％不足すると予測されています。

パーキンソン病治療薬市場レポートハイライト

薬物クラス別では、PDの有病率が高く、疾患治療用の薬剤が容易に入手できることから、2021年にはカルビドパ・レボドパセグメントが最大の売上シェアを占めました*2021年には小売薬局流通チャネルセグメントが世界の業界を支配しました。

これは、WalgreensやWalmartを含む老舗の小売薬局チェーンでPD治療薬が容易に入手できることに起因する

新製品の市場参入により、予測期間中はアジア太平洋地域が最も成長すると予想される

2020年6月、小野薬品工業株式会社は、日本におけるPD患者の治療薬としてOngentysの製造販売承認を取得しました

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
  • セグメントの範囲
  • 地域範囲
• 調査手法
• 情報調達
  • 購入したデータベース：
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ：商品フローアプローチ
• 調査の仮定
• 二次情報一覧
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場の見通し

第3章 パーキンソン病治療薬市場の変数、動向、および範囲

• 親市場の見通し
  • 中枢神経系治療薬市場
• 浸透と成長の見通しのマッピング
• 規制と償還のシナリオ
• 市場促進要因分析
  • パーキンソン病の有病率の増加
  • 強力なパイプラインの存在
  • 新規ドラッグデリバリーシステムのイントロダクション
• 市場抑制要因分析
  • 治療費が高い
  • 神経内科医と脳神経外科医の不足
• 主要取引と戦略的提携
• パイプライン分析
• 要因別SWOT分析（政治と法律、経済、技術）
• 業界分析- ポーターズ

第4章 パーキンソン病治療薬市場：競合分析

• 主要な市場参入企業別最近の動向と影響分析
  • 新製品の発売
  • 合併と買収
  • パートナーシップと戦略的コラボレーション
  • カンファレンスとキャンペーン
• 会社の分類
  • イノベーター
  • 市場のリーダー
  • ヒートマップ分析
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
• 主要企業の市場シェア分析、2021年
• 公開会社
  • 企業の市況分析
  • 競合ダッシュボード分析
    • 市場の差別化要因
• 非公開会社
  • 主要新興企業一覧
  • 地域ネットワークマップ

第5章 パーキンソン病治療薬市場：セグメント分析、薬剤クラス別、2018年～2030年（100万米ドル）

• パーキンソン病治療市場：薬剤クラスの変動分析
• カルビドパ-レボドパ
• ドーパミン作動薬
• MAO-B阻害剤
• COMT阻害剤
• 抗コリン薬
• その他

第6章 パーキンソン病治療薬市場：セグメント分析、流通チャネル別、2018年から2030年（100万米ドル）

• パーキンソン病治療市場：流通チャネル変動分析
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 パーキンソン病治療薬市場：セグメント分析、地域別、2018年から2030年（100万米ドル）

• 定義と範囲
• 地域市場シェア分析、2021年および2030年
• 地域市場のスナップショット
• 市場規模、予測、収益、トレンド分析、2021年から2030年
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • スペイン
    • フランス
    • イタリア
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • MEA
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 パーキンソン病治療薬市場：企業プロファイル

• 企業プロファイル
  • Cerevel Therapeutics
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の展開
  • Novartis AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Teva Pharmaceutical Industries Ltd
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Merck &Co., Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • GlaxoSmithKline plc.（GSK）
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • AbbVie, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • H. Lundbeck A/S
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
  • Amneal Pharmaceuticals LLC.
    • 会社概要
    • 金融ベンチマーク
    • 製品のベンチマーク
    • 最近の開発
  • Supernus Pharmaceuticals, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Global Parkinson's Disease Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 4 Global Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 5 Global Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 6 North America Parkinson's Disease Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 8 North America Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 9 U.S. Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 10 U.S. Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 11 Canada Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 12 Canada Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Europe Parkinson's Disease Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 14 Europe Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 15 Europe Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Germany Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 17 Germany Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 U.K. Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 19 U.K. Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 France Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 21 France Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Italy Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 23 Italy Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 24 Spain Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 25 Spain Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Asia Pacific Parkinson's Disease Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 27 Asia Pacific Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 Japan Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 30 Japan Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 China Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 32 China Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 India Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 34 India Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 South Korea Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 36 South Korea Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Australia Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 38 Australia Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 39 Latin America Parkinson's Disease Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 40 Latin America Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 41 Latin America Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 Brazil Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 43 Brazil Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Mexico Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 45 Mexico Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Argentina Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 47 Argentina Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Middle East & Africa Parkinson's Disease Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 49 Middle East & Africa Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 50 Middle East & Africa Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Saudi Arabia Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 52 Saudi Arabia Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 South Africa Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 54 South Africa Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 UAE Parkinson's Disease Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 56 UAE Parkinson's Disease Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Parkinson's Disease Treatment Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Information Procurement
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value-Chain-Based Sizing & Forecasting
• Fig. 7 QFD Modeling for Market Share Assessment
• Fig. 8 Market Formulation & Validation

Fig. 9 Market Outlook (2021)

• Fig. 10 Penetration and Growth Prospect Mapping
• Fig. 11 Parkinson's Disease Treatment Market Driver Impact
• Fig. 12 Parkinson's Disease Treatment Market Restraint Impact
• Fig. 13 Major Deals and Strategic Alliances
• Fig. 14 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
• Fig. 15 Porter's Five Forces Analysis
• Fig. 16 Heat Map Analysis
• Fig. 17 Company Market Share Analysis (2021)
• Fig. 18 Company Market Position Analysis (2021), Revenue Analysis
• Fig. 19 Company Market Position Analysis (2021), Profit Margin Analysis
• Fig. 20 Market Differentiators
• Fig. 21 Regional Network Map
• Fig. 22 Parkinson's Disease Treatment Market Drug Class Outlook: Key Takeaways
• Fig. 23 Parkinson's Disease Treatment Market: Drug Class Movement Analysis
• Fig. 24 Carbidopa-Levodopa Market, 2018 - 2030 (USD Million)
• Fig. 25 Dopamine Agonist Market, 2018 - 2030 (USD Million)
• Fig. 26 MAO-B Inhibitors Market, 2018 - 2030 (USD Million)
• Fig. 27 COMT Inhibitors Market, 2018 - 2030 (USD Million)
• Fig. 28 Anticholinergics Market, 2018 - 2030 (USD Million)
• Fig. 29 Others Market, 2018 - 2030 (USD Million)
• Fig. 30 Parkinson's Disease Treatment Market Distribution Channel Outlook: Key Takeaways
• Fig. 31 Parkinson's Disease Treatment Market: Distribution Channel Movement Analysis
• Fig. 32 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• Fig. 33 Retail Pharmacy Market, 2018 - 2030 (USD Million)
• Fig. 34 Online Pharmacy Market, 2018 - 2030 (USD Million)
• Fig. 35 Regional Outlook, 2020 & 2030
• Fig. 36 Regional Marketplace: Key Takeaways
• Fig. 37 North America
• Fig. 38 North America Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 39 U.S.
• Fig. 40 U.S. Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 41 Canada
• Fig. 42 Canada Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 43 Europe
• Fig. 44 Europe Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 45 U.K.
• Fig. 46 U.K. Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 47 Germany
• Fig. 48 Germany Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 49 Spain
• Fig. 50 Spain Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 51 France
• Fig. 52 France Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 53 Italy
• Fig. 54 Italy Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 55 Asia Pacific
• Fig. 56 Asia Pacific Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 57 Japan
• Fig. 58 Japan Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 59 China
• Fig. 60 China Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 61 India
• Fig. 62 India Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 63 South Korea
• Fig. 64 South Korea Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 65 Australia
• Fig. 66 Australia Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 67 Latin America
• Fig. 68 Latin America Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 69 Brazil
• Fig. 70 Brazil Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 71 Mexico
• Fig. 72 Mexico Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 73 Argentina
• Fig. 74 Argentina Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 75 Middle East and Africa
• Fig. 76 MEA Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 77 South Africa
• Fig. 78 South Africa Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 79 Saudi Arabia
• Fig. 80 Saudi Arabia Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)
• Fig. 81 UAE
• Fig. 82 UAE Parkinson's Disease Treatment Market, 2018 - 2030 (USD Million)

Parkinson's Disease Treatment Market Growth & Trends:

The global Parkinson's disease treatment market size is expected to reach USD 11.98 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 12.1% from 2022 to 2030. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson's Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson's Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson's Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

Parkinson's Disease Treatment Market Report Highlights:

• By drug class, the Carbidopa-Levodopa segment held the largest revenue share in 2021 due to the high prevalence of PD and easy drug availability for the disease treatment* The retail pharmacy distribution channel segment dominated the global industry in 2021

• This is due to the easy availability of PD drugs in well-established retail pharmacy chains including Walgreens and Walmart

• Asia Pacific is expected to be the fastest-growing region during the forecast period due to the entry of new products into the market

• In June 2020, Ono Pharmaceutical Co., Ltd. received manufacturing and marketing approval for Ongentys to treat patients with PD in Japan

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment scope
  • 1.1.2 Regional scope
  • 1.1.3 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database:
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3

Chapter 2 Executive Summary

• 2.1 Market Outlook

Chapter 3 Parkinson's Disease Treatment Market Variables, Trends, and Scope

• 3.1 Parent Market Outlook
  • 3.1.1 Central Nervous System Therapeutics Market
• 3.2 Penetration and Growth Prospect Mapping
• 3.3 Regulatory & Reimbursement Scenario
• 3.4 Market Driver Analysis
  • 3.4.1 Increasing prevalence of Parkinson's disease
  • 3.4.2 Presence of strong pipeline drugs
  • 3.4.3 Introduction of novel drug delivery systems
• 3.5 Market Restraint Analysis
  • 3.5.1 High treatment cost
  • 3.5.2 Lack of neurologist and neurosurgeons
• 3.6 Major Deals and Strategic Alliances
• 3.7 Pipeline Analysis
• 3.8 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.9 Industry Analysis - Porter's

Chapter 4 Parkinson's Disease Treatment Market: Competitive Analysis

• 4.1 Recent Developments and Impact Analysis, by Key Market Participants
  • 4.1.1 New Product Launches
  • 4.1.2 Mergers and Acquisitions
  • 4.1.3 Partnerships and Strategic Collaboration
  • 4.1.4 Conferences and Campaigns
• 4.2 Company Categorization
  • 4.2.1 Innovators
  • 4.2.2 Market Leaders
  • 4.2.3 Heat map analysis
• 4.3 Vendor Landscape
  • 4.3.1 List of key distributors and channel partners
  • 4.3.2 Key customers
• 4.4 Key Company Market Share Analysis, 2021
• 4.5 Public Companies
  • 4.5.1 Company market position analysis
  • 4.5.2 Competitive dashboard analysis
    • 4.5.2.1 Market Differentiators
• 4.6 Private Companies
  • 4.6.1 List of key emerging companies
  • 4.6.2 Regional Network Map

Chapter 5 Parkinson's Disease Treatment Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

• 5.1 Parkinson's Disease Treatment Market: Drug Class Movement Analysis
• 5.2 Carbidopa-Levodopa
  • 5.2.1 Carbidopa-levodopa market, 2018 - 2030 (USD Million)
• 5.3 Dopamine Agonists
  • 5.3.1 Dopamine agonists market, 2018 - 2030 (USD Million)
• 5.4 MAO-B Inhibitors
  • 5.4.1 MAO-B inhibitors market, 2018 - 2030 (USD Million)
• 5.5 COMT inhibitors
  • 5.5.1 COMT inhibitors market, 2018 - 2030 (USD Million)
• 5.6 Anticholinergics
  • 5.6.1 Anticholinergics market, 2018 - 2030 (USD Million)
• 5.7 Others
  • 5.7.1 Others market, 2018 - 2030 (USD Million)

Chapter 6 Parkinson's Disease Treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Parkinson's Disease Treatment Market: Distribution Channel Movement Analysis
• 6.2 Hospital Pharmacy
  • 6.2.1 Hospital pharmacy market, 2018 - 2030 (USD Million)
• 6.3 Retail Pharmacy
  • 6.3.1 Retail pharmacy market, 2018 - 2030 (USD Million)
• 6.4 Online Pharmacy
  • 6.4.1 Online pharmacy market, 2018 - 2030 (USD Million)

Chapter 7 Parkinson's Disease Treatment Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2021 & 2030
• 7.3 Regional Market Snapshot
• 7.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
  • 7.4.1 North America
    • 7.4.1.1 North America Parkinson's disease treatment, 2018-2030 (USD Million)
    • 7.4.1.2 U.S.
    • 7.4.1.2.1 U.S. Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.1.3 Canada
    • 7.4.1.3.1 Canada Parkinson's disease treatment market, 2018 - 2030 (USD Million)
  • 7.4.2 Europe
    • 7.4.2.1 Europe Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.2.2 U.K.
    • 7.4.2.2.1 U.K. Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.2.3 Germany
    • 7.4.2.3.1 Germany Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.2.4 Spain
    • 7.4.2.4.1 Spain Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.2.5 France
    • 7.4.2.5.1 France Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.2.6 Italy
    • 7.4.2.6.1 Italy Parkinson's disease treatment market, 2018 - 2030 (USD Million)
  • 7.4.3 Asia Pacific
    • 7.4.3.1 Asia Pacific Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.3.2 Japan
    • 7.4.3.2.1 Japan Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.3.3 China
    • 7.4.3.3.1 China Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.3.4 India
    • 7.4.3.4.1 India Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.3.5 South Korea
    • 7.4.3.5.1 South Korea Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.3.6 Australia
    • 7.4.3.6.1 Australia Parkinson's disease treatment market, 2018 - 2030 (USD Million)
  • 7.4.4 Latin America
    • 7.4.4.1 Latin America Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.4.2 Brazil
    • 7.4.4.2.1 Brazil Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.4.3 Mexico
    • 7.4.4.3.1 Mexico Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.4.4 Argentina
    • 7.4.4.4.1 Argentina Parkinson's disease treatment market, 2018 - 2030 (USD Million)
  • 7.4.5 MEA
    • 7.4.5.1 MEA Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.5.2 South Africa
    • 7.4.5.2.1 South Africa Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.5.3 Saudi Arabia
    • 7.4.5.3.1 Saudi Arabia Parkinson's disease treatment market, 2018 - 2030 (USD Million)
    • 7.4.5.4 UAE
    • 7.4.5.4.1 UAE Parkinson's disease treatment market, 2018 - 2030 (USD Million)

Chapter 8 Parkinson's Disease Treatment Market: Company Profiles

• 8.1 Company Profiles
  • 8.1.1 Cerevel Therapeutics
    • 8.1.1.1 Company Overview
    • 8.1.1.2 Financial Performance
    • 8.1.1.3 Product Benchmarking
    • 8.1.1.4 recent Developments
  • 8.1.2 Novartis AG
    • 8.1.2.1 Company Overview
    • 8.1.2.2 Financial Performance
    • 8.1.2.3 Product Benchmarking
    • 8.1.2.4 Recent Developments
  • 8.1.3 Teva Pharmaceutical Industries Ltd
    • 8.1.3.1 Company Overview
    • 8.1.3.2 Financial Performance
    • 8.1.3.3 Product Benchmarking
    • 8.1.3.4 Recent Developments
  • 8.1.4 Merck & Co., Inc.
    • 8.1.4.1 Company Overview
    • 8.1.4.2 Financial Performance
    • 8.1.4.3 Product Benchmarking
    • 8.1.4.4 Recent Developments
  • 8.1.5 GlaxoSmithKline plc. (GSK)
    • 8.1.5.1 Company Overview
    • 8.1.5.2 Financial Performance
    • 8.1.5.3 Product Benchmarking
    • 8.1.5.4 Recent Developments
  • 8.1.6 AbbVie, Inc.
    • 8.1.6.1 Company Overview
    • 8.1.6.2 Financial Performance
    • 8.1.6.3 Product Benchmarking
    • 8.1.6.5 Recent Developments
  • 8.1.7 H. Lundbeck A/S
    • 8.1.7.1 Company Overview
    • 8.1.7.2 Financial Performance
    • 8.1.7.3 Product Benchmarking
  • 8.1.8 Amneal Pharmaceuticals LLC.
    • 8.1.8.1 Company Overview
    • 8.1.8.3 Financial Benchmarking
    • 8.1.8.4 Product Benchmarking
    • 8.1.8.5 Recent Developments
  • 8.1.9 Supernus Pharmaceuticals, Inc.
    • 8.1.9.1 Company Overview
    • 8.1.9.2 Financial performance
    • 8.1.9.3 Product Benchmarking
    • 8.1.9.4 Recent Developments